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Background: Faecal immunochemical tests for haemoglobin (FIT) are becoming 
widely used in colorectal cancer screening and assessment of symptomatic patients. 
Faecal haemoglobin concentration (f-Hb) thresholds are used to guide subsequent 
investigation. We established the distributions of f-Hb in a large screening population 
by sex, age, deprivation and geography. 
 
Methods: Single estimates of f-Hb were documented for all individuals participating 
in the first 18 months of the Scottish Bowel Screening Programme (SBoSP).  The 
distributions of f-Hb were generated for all participants, all men and women, and 
men and woman by age quintile and deprivation quintile. Distributions were also 
generated by geographical region for all participants, men and women, and by 
deprivation. Comparisons of f-Hb distributions with those found in a pilot evaluation 
of FIT and three other countries were performed. 
 
Results: f-Hb was documented for 887,248 screening participants, 422,385 men 
and 464,863 women. f-Hb varied by sex, age, deprivation quintile and geographical 
region.  The f-Hb distributions by sex and age differed between the SBoSP and the 
pilot evaluation and the three other countries. 
 
Conclusions: f-Hb is higher in men than women and increases with age and 
deprivation in both sexes. f-Hb also varies by geographical region, independently of 
deprivation, and by country.   The f-Hb distribution estimated by pilot evaluation may 
not represent the population distribution.  Decision limits have advantages over 
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reference intervals.  Use of partitioned f-Hb thresholds for further investigation, 
based on the data generated, have advantages and disadvantages, as do risk 






Colorectal cancer (CRC) incidence and mortality rates vary markedly from country to 
country but, globally, CRC is the third most commonly diagnosed cancer in men and 
the second in women, with 1.8 million new cases and almost 861,000 deaths in 
2018, according to the World Health Organization. (1) However, early detection can 
be achieved using quantitative faecal immunochemical tests for haemoglobin (FIT), 
which measure faecal haemoglobin concentration (f-Hb), leading to better outcomes 
for individuals. FIT can be used in asymptomatic population screening, (2) in 
assessment of patients presenting with lower bowel symptoms, (3) and in adenoma 
surveillance programmes. (4) In general, in all these clinical settings, a single f-Hb 
threshold is set to decide which individuals should be invited for further investigation, 
usually colonoscopy.  The threshold applied varies according to the clinical setting 
and differs considerably from country to country, and even from region to region in a 
country.   
 
In asymptomatic population-based screening, only one f-Hb threshold is generally 
used in any programme, such as 80 µg Hb/g faeces in the Scottish Bowel Screening 
Programme (SBoSP), although this has been widely criticised.  We have shown that 
f-Hb is higher in men than women and rises with age and have documented the 
effect of these variables on screening programme positivity and future risk of 
colorectal neoplasia. (5) We have also suggested that, while f-Hb was higher in men 
than women and rose with age in Taiwan, Florence and Barcelona, (6,7) as well as 
in Scotland, the data are not transferrable over geography.  Further, we have shown 
that f-Hb increases with socio-economic deprivation. (8) These findings have been 
6 
 
confirmed in studies from South Australia (9) and England. (10) In addition, other 
variables affect f-Hb; for example, f-Hb is higher in prevalence than in incidence 
screening. (11) Further, pre-analytical and analytical variables, including specimen 
temperature and collection device buffer formulation, affect f-Hb. (12)  
 
In consequence, there have been several studies, recently reviewed, concerning the 
use of different thresholds for men and women and for different age groups to 
enhance the equality of outcomes for all individuals. (13)  Most studies to date 
conclude that further work is needed, for example, Brenner et al (14) state that: 
“there are major differences in diagnostic performance parameters according to sex 
and age, which should receive careful attention in the interpretation and comparison 
of results of FIT-based CRC screening studies.”  Rather than simply using different 
thresholds according to sex and age, a strategy that is now creating significant 
interest is the creation and application of risk scores, mathematical algorithms based 
on variables known to affect CRC incidence, including sex, age, deprivation and 
many other possible variables. A recent review described published risk scores for 
colorectal neoplasia and identified 87 variables (excluding major genetic variants and 
single nucleotide polymorphisms) that had been applied across all studies examined: 
a few include f-Hb. (15)   
 
Scotland began CRC screening in 2000 with three pilot screening rounds based 
upon use of guaiac-based faecal occult blood tests (gFOBT). (16) The first fully 
rolled out national CRC screening programme in the world then commenced in 2007 
with a two-tier reflex gFOBT/qualitative FIT strategy. (17) It became abundantly clear 
that FIT had many advantages over gFOBT (2) and a pilot evaluation of FIT as a 
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first-line test (FFLT) was conducted in 2010. (18) In November 2017, the SBoSP 
evolved to use quantitative FIT as the primary screening test. (19)  
 
We have here generated the f-Hb distributions by sex, age, deprivation in detail and, 
for the first time, geographical region, derived from the data generated from a 
screening population of almost one million participants. We have examined the 
implications for screening, reference values, the use of stratified f-Hb thresholds and 
the creation and application of risk scores.  We also assessed whether the data on f-
Hb from the FFLT pilot evaluation (5,8) informed or confounded the decision made 
on the threshold set in the SBoSP and compared f-Hb distributions from both SBoSP 




The details of the SBoSP have been documented previously. (16,17) Regular 
updates on the key performance indicators are published and available on the 
Internet. (20)  In brief, in the FIT-based SBoSP, one FIT specimen collection device 
(Hitachi Chemical Diagnostic Systems Co., Ltd, Tokyo, Japan) is sent in the post 
every two years to all men and women registered with a General Practitioner (GP)  
and aged between 50 and 74 years, with older age opt-in, along with information on 
the SBoSP, instructions on how to collect and handle the sample and a pre-paid 
envelope for return of the device to the Scottish Bowel Screening Laboratory 
(SBoSL).  Evaluable devices returned are analysed on one of four HM-JACKarc FIT 
systems (Hitachi Chemical Diagnostic Systems Co., Ltd) in the SBoSL, which has 
International Organization for Standardization (ISO) 15189 accreditation.   Total 
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quality management is comprehensively practiced, including internal quality control 
and external quality assessment carried out by the UK National External Quality 
Assessment Scheme.  Data from every participant on f-Hb, sex, age in quintiles, 
degree of deprivation in quintiles and National Health Service (NHS) Board of 
residence were available from the Bowel Screening Scotland (BoSS) system.  
Deprivation was assessed using the Scottish Index of Multiple Deprivation (SIMD), a 
measure of the extent to which an area is deprived across seven domains: income, 
employment, education, health, access to services, crime and housing. (21) The 
centiles of f-Hb distributions from the data in the first 18 months of the FIT-based 
SBoSP (November 2017 to April 2018) were created by the Information Services 
Division (ISD) of National Services Scotland (NSS). 
 
As described in detail previously, (18) the FFLT evaluation was carried out in two 
NHS Boards (Tayside, and Ayrshire and Arran) in 2010; every eligible person was 
sent a specimen collection device for the OC-Sensor Diana (Eiken Chemical Co., 
Ltd, Tokyo, Japan), along with information on how to perform the test and on the 
SBoSP, along with a return envelope.  Analysis was performed on one of two OC-
Sensor Diana FIT systems (Eiken Chemical Co., Ltd, Tokyo, Japan) in the SBoSL. 
Data on f-Hb centiles by age and sex from the FFLT were compared to those in the 
SBoSP to investigate to what extent the pilot evaluation had informed, or 
confounded, the subsequent performance of the SBoSP in the whole population and 
were also compared to previously published data from three other countries. (6,7) R 








The 90th, 95th and 97.5th centiles for all 887,248 participants in the first 18 months of 
the FIT-based SBoSP are shown in Table 1.  The centiles documented are those for 
which the f-Hb was greater than the limit of detection of the FIT system used, 2 µg 
Hb/g faeces, since f-Hb lower than this are indistinguishable from samples with no 
Hb. (22)  The 95th centiles of f-Hb in all participants by sex, and by sex and age 
quintile (years), are shown in Figure 1. As in previous studies, (5-7,9,10), overall the 
422,385 men had higher f-Hb than the 464,863 women.  Further, when grouped by 
age quintile, 50-54, 55-59, 60-64, 65-69 and 70 years or more, f-Hb rose with age in 
both men and women. 
 
Table 1. Centiles of distribution of faecal haemoglobin concentration (µg Hb/g 
faeces) for all participants, all men and women, and all men and all women by 









97.5th        
All All All 887,248 13.6 40.2 105.4        
All Men All 422,385 17.5 49.9 136.1 
All Women All 464,863 10.5 32.2 82.5        
50-54 Men All 105,861 9.3 30.1 83.4 
55-59 Men All 77,312 12.9 39.0 104.6 
60-64 Men All 98,442 18.3 50.5 140.9 
65-69 Men All 68,073 23.8 64.9 179.3 
70+ Men All 72,697 29.4 77.6 216.1 
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50-54 Women All 116,406 6.2 21.2 60.5 
55-59 Women All 85,044 7.8 25.8 69.9 
60-64 Women All 108,357 10.5 31.3 80.0 
65-69 Women All 73,858 13.7 39.6 98.2 
70+ Women All 81,198 17.7 47.6 116.8 
 
The 90th, 95th and 97.5th centiles of f-Hb, grouped by sex and SIMD quintile, and age 
are shown in Table 2. The 95th centiles of f-Hb in men by age quintile (years) and 
Scottish Index of Multiple Deprivation (SIMD) quintile are shown in Figure 2: women 
show a similar pattern but with lower f-Hb. Once again, f-Hb is higher in men than 
women and rises with age; the new data here confirm, in much more detail than 
previously published (8,9), that f-Hb rises with deprivation. Further, f-Hb rises with 
increasing deprivation in both men and women and throughout the age gradient. 
 
Table 2. Centiles of distribution of faecal haemoglobin concentration (µg Hb/g 
faeces) for all men and women by age quintile (years) and by increasing 
deprivation by Scottish Index of Multiple Morbidity (SIMD): 5 = least deprived: 










       
50-54 Men 5  23,814 6.0 20.1 59.3 
50-54 Men 4 23,843 7.5 25.3 70.0 
50-54 Men 3 21,613 8.7 26.8 72.5 
50-54 Men 2 19,275 11.0 37.3 99.9 
50-54 Men 1  17,204 16.3 51.2 155.7        
55-59 Men 5  17,060 8.5 25.9 72.3 
55-59 Men 4 17,589 10.1 29.1 87.2 
55-59 Men 3 16,085 12.1 35.9 88.2 
55-59 Men 2 14,036 15.8 46.4 125.2 
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55-59 Men 1 12,468 23.1 68.1 190.6        
60-64 Men 5 22,510 13.1 38.2 101.2 
60-64 Men 4 22,470 14.4 39.7 101.8 
60-64 Men 3 20,736 18.2 52.1 146.3 
60-64 Men 2 17,958 23.4 61.0 181.7 
60-64 Men 1 14,686 27.8 78.8 234.7        
65-69 Men 5  15,797 16.8 47.0 120.6 
65-69 Men 4 16,014 19.6 54.1 148.4 
65-69 Men 3 14,406 23.2 65.6 192.1 
65-69 Men 2 12,249 30.5 85.5 243.0 
65-69 Men 1  9,567 36.7 97.2 263.1        
70+ Men 5 17,059 22.3 62.3 162.3 
70+ Men 4 17,147 24.5 67.7 175.4 
70+ Men 3 15,827 29.1 76.5 199.0 
70+ Men 2 13,034 34.9 88.1 259.8 
70+ Male 1  9,582 42.6 123.1 389.4        
50-54 Women 5  26,828 4.1 14.9 43.0 
50-54 Women 4 26,362 5.0 16.9 47.1 
50-54 Women 3 24,146 5.7 19.3 54.7 
50-54 Women 2 20,902 7.7 25.7 74.1 
50-54 Women 1  18,087 11.7 39.5 101.2        
55-59 Women 5  18,979 4.9 17.0 48.9 
55-59 Women 4 19,670 6.0 20.0 55.8 
55-59 Women 3 18,137 7.6 23.4 66.6 
55-59 Women 2 15,355 10.3 32.3 87.7 
55-59 Women 1  12,848 14.2 42.7 116.6        
60-64 Women 5  25,356 6.9 21.2 50.7 
60-64 Women 4 24,775 8.4 25.4 61.2 
60-64 Women 3 22,782 10.5 31.3 82.2 
60-64 Women 2 19,857 13.4 37.4 100.2 
60-64 Women 1  15,527 19.2 54.3 131.6        
65-69 Women 5  17,222 9.1 28.3 74.6 
65-69 Women 4 17,393 11.3 34.2 89.2 
65-69 Women 3 15,589 13.6 38.6 93.6 
65-69 Women 2 13,430 17.0 45.4 113.2 
65-69 Women 1  10,182 23.4 63.1 151.4        
70+ Women 5  18,949 13.5 36.9 87.2 
70+ Women 4 18,656 13.5 38.7 89.1 
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70+ Women 3 17,545 17.0 46.4 109.5 
70+ Women 2 14,980 20.8 56.1 148.6 
70+ Women 1 11,036 30.6 71.8 207.3 
 
The 90th, 95th and 97.5th centiles of distribution of f-Hb for all men and women in four 
age groups (years) for the FIT-based Scottish Bowel Screening Programme in the 
two pilot evaluation NHS Boards, NHS Tayside and NHS Ayrshire and Arran (SBoSP 
TA&A), in the FIT as a first-line test pilot evaluation (FFLT) and in Taiwan, Florence 
and Barcelona are shown in Table 3. The 95th centiles of f-Hb in men in these 
cohorts in four age groups (years) are shown in Figure 3: women show a similar 
pattern but with lower f-Hb. The differences between the f-Hb from the FIT-based 
SBoSP and the FFLT evaluation are striking, the f-Hb being higher in both men and 
women in all age groups in the same two NHS Boards in the SBoSP and FFLT. The 
data on the f-Hb distributions from the FIT-based SBoSP also differ from those from 
the three other countries, (5,6) confirming that, while f-Hb is higher in men than in 
women in all age groups, and rises with age in all countries investigated, Scotland 
remains different to other countries.   
 
 
Table 3. Centiles of distribution of faecal haemoglobin concentration (µg Hb/g 
faeces) for all men and women in four age groups (years) for two NHS Boards 
in the FIT-based Scottish Bowel Screening Programme, NHS Tayside and NHS 
Ayrshire and Arran (SBoSP TA&A), FIT as a first-line test pilot evaluation 











97.5th        
50-54 Men SBoSP TA&A 15,332 9.2 28.0 78.6 
55-59 Men SBoSP TA&A 10,625 12.6 35.7 101.5 
60-64 Men SBoSP TA&A 15,851 18.1 48.9 134.9 
65-69 Men SBoSP TA&A 11,287 22.5 57.6 179.6        
50-54 Men FFLT 4,075 7.0 20.8 56.2 
55-59 Men FFLT 4,160 9.6 30.8 83.0 
60-64 Men FFLT 3,489 12.4 37.0 104.0 
65-69 Men FFLT 3,497 19.6 50.6 142.6        
50-54 Men Taiwan 11,321 7.2 17.2 42.8 
55-59 Men Taiwan 9,769 9.2 22.6 68.4 
60-64 Men Taiwan 8,719 12.6 29.4 81.0 
65-69 Men Taiwan 10,150 15.4 37.8 99.0        
50-54 Men Florence 793 4.4 10.4 32.8 
55-59 Men Florence 1,093 3.6 11.0 23.2 
60-64 Men Florence 1,105 8.8 21.2 77.0 
65-69 Men Florence 1,094 5.6 16.4 55.4        
50-54 Men Barcelona 9,465 7.2 27.2 93.0 
55-59 Men Barcelona 7,834 11.4 48.0 157.2 
60-64 Men Barcelona 8,024 19.2 69.4 195.8 
65-69 Male Barcelona 6,311 22.2 81.0 259.8 
       
50-54 Women SBoSP TA&A 16,898 6.1 20.9 60.7 
55-59 Women SBoSP TA&A 12,087 7.5 26.8 67.6 
60-64 Women SBoSP TA&A 17,706 10.0 31.0 84.8 
65-69 Women SBoSP TA&A 12,405 12.8 36.7 90.5 
       
50-54 Women FFLT 4,543 4.6 13.6 34.0 
55-59 Women FFLT 4,730 6.2 18.4 48.8 
60-64 Women FFLT 4,058 6.8 20.2 47.0 
65-69 Women FFLT 3,985 9.0 25.8 63.4 
       
50-54 Women Taiwan 18,476 6.8 14.4 27.4 
55-59 Women Taiwan 13,959 7.2 15.8 28.4 
60-64 Women Taiwan 12,350 9.4 18.8 39.2 
65-69 Women Taiwan 12,444 11.0 22.8 50.4        
50-54 Women Florence 1,031 3.4 6.4 14.6 
55-59 Women Florence 1,272 3.4 8.4 17.8 
60-64 Women Florence 1,241 3.6 8.8 20.8 
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65-69 Women Florence 1,188 5.2 15.0 44.0        
50-54 Women Barcelona 11,520 3.4 11.2 34.6 
55-59 Women Barcelona 9,922 4.8 19.0 55.0 
60-64 Women Barcelona 10,076 7.2 28.0 86.8 
65-69 Women Barcelona 7,623 9.2 28.4 76.2 
 
We explored whether geographical region in Scotland affected f-Hb generating data 
based upon all 14 NHS Boards responsible for the protection and the improvement 
of their population's health and for the delivery of frontline healthcare services.  The 
90th, 95th and 97.5th centiles are shown in Table 4 for all participants and for men and 
women. Again, men have higher f-Hb than women; importantly, there are clear 
differences between geographical regions.  Since this might well be due to socio-
economic factors, we explored the centiles of f-Hb for the 11 mainland NHS Boards 
in Scotland by SIMD quintile: these data are shown in Supplementary Table 1, which 
documents that there are differences across geographical regions.  
 
 
Table 4. Centiles of distribution of faecal haemoglobin concentration for all 
participants and all men and women in four age groups (years) by 
geographical region (NHS Board) in Scotland. 
Sex 
Geographical region by 







All Ayrshire and Arran 66,248 14.7 41.1 114.1 
All Borders 24,528 10.6 33.2 83.2 
All Dumfries and Galloway 29,734 11.0 34.2 85.3 
All Fife 62,878 12.2 37.5 96.9 
All Forth Valley 52,042 12.9 37.8 103.7 
All Grampian 96,914 12.5 37.9 101.7 
All Greater Glasgow and Clyde 168,886 16.5 47.4 123.2 
All Highland 64,212 12.9 38.7 99.7 
All Lanarkshire 104,353 16.7 46.5 124.6 
All Lothian 132,391 11.6 35.4 93.3 
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All Orkney 4,213 9.0 25.2 60.2 
All Shetland 4,408 13.5 39.3 103.6 
All Tayside 71,368 12.1 36.5 92.9 
All Western Isles 5,073 18.0 48.6 123.1 
      
Men Ayrshire and Arran 31,122 19.2 51.3 145.1 
Men Borders 11,647 13.6 40.7 91.9 
Men Dumfries and Galloway 14,040 14.1 39.2 101.4 
Men Fife 29,990 16.0 48.3 126.7 
Men Forth Valley 24,784 16.1 47.1 130.4 
Men Grampian 46,980 15.7 46.4 127.9 
Men Greater Glasgow and Clyde 80,054 20.6 58.9 167.2 
Men Highland 30,800 18.0 50.8 136.2 
Men Lanarkshire 49,531 21.3 57.5 165.4 
Men Lothian 62,913 15.1 44.7 121.5 
Men Orkney 1,993 10.9 29.1 73.0 
Men Shetland 2,182 17.7 48.1 110.5 
Men Tayside 33,917 15.9 44.5 121.9 
Men Western Isles 2,432 22.0 56.2 146.5 
      
Women Ayrshire and Arran 35,126 11.3 34.2 91.1 
Women Borders 12,881 8.3 26.5 69.8 
Women Dumfries and Galloway 15,694 8.4 28.0 75.0 
Women Fife 32,888 9.1 27.6 73.4 
Women Forth Valley 27,258 10.3 31.4 84.7 
Women Grampian 49,934 9.7 30.6 79.7 
Women Greater Glasgow and Clyde 88,832 13.0 38.2 91.7 
Women Highland 33,412 9.2 28.7 71.6 
Women Lanarkshire 54,822 13.2 37.8 96.3 
Women Lothian 69,478 8.9 27.7 73.4 
Women Orkney 2,220 7.4 22.7 54.1 
Women Shetland 2,226 9.8 29.3 88.3 
Women Tayside 37,451 9.2 28.8 74.9 





We have confirmed that f-Hb is higher in men than women and increases with age in 
both sexes and, in the greatest detail available to date, we have shown that f-Hb 
increases with increasing deprivation in both men and women and in all age groups. 
16 
 
Further, we have shown for the first time that, even in a small country, there are 
large variations in f-Hb in screening participants across geographical regions.  These 
data here explain the observed differences in positivity in the SBoSP among men 
and women, in deprivation categories, and across NHS Boards, unsurprisingly, 
because positivity is a surrogate marker for f-Hb. (23) 
 
A major strength of this study is that the number of participants studied are large. 
Further, the SBoSP invites individuals every two years and the data presented here 
are from the first 18 months of the FIT-based SBoSP, meaning that no individual will 
have contributed more than one f-Hb result. In addition, being based on an 
asymptomatic population-based screening programme, the participants fulfil the 
requirements of being described as reference individuals, with some caveats. 
Moreover, the data were generated in a single laboratory, accredited to internal 
standards, by with staff whose sole function is f-Hb examination.  A weakness is that 
it has been shown that positivity and f-Hb decrease from incidence to prevalence 
screening rounds: our data are derived from a mixture of participants in incidence 
and prevalence screening rounds and the percentage of those in the incidence round 
is likely to be higher than previously in the FFLT because of the increase in uptake 
across all groups, but particularly among men, younger participants and more 
deprived participants. (20) A further strength is that the data on f-Hb from the FFLT, 
Taiwan, Florence and Barcelona were published only after peer-review. Another 
strength is that we were able to dissect the f-Hb distribution data for the two NHS 
Boards that participated in the FFLT to better examine whether the pilot evaluation 
provided results that informed or confounded. A weakness is that the results from the 
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comparison studies were performed some years ago and the f-Hb distributions in 
Taiwan, Florence and Barcelona may have changed over time.  
 
Brenner et al. (24) documented differences in the test performance of FIT in men 
and women in a screening programme and suggested some plausible reasons for 
the sex difference, including that colonic transit time is slower in women than in men 
(25), which could result in more degradation of f-Hb passed into the gut before 
excretion of faeces. However, this may be too simplistic, for example, constipation is 
more prevalent not only in females, but also with increasing age and deprivation. 
(26) The reasons for the increase in f-Hb with age are still unclear but may be due to 
increasing inherent systemic inflammation. (27) The higher f-Hb in deprivation are 
probably due to lifestyle factors, including higher levels of obesity, (28) sedentary 
lifestyles, (29) poor diets (30) and similar factors influencing the inflammatory status 
of the gut in the more deprived.  
 
The differences between the results from the FIT-based SBoSP and the FFLT are 
striking despite using the same threshold (80 µg Hb/g faeces).  The f-Hb is higher in 
both men and women in all age groups in the SBoSP: this explains the higher overall 
positivity than that found in the FFLT pilot evaluation. (19) There are several 
plausible reasons for the discrepancies.  Firstly, the quantitative FIT system used in 
the SBoSP (HM-JACKarc, Hitachi Chemical Diagnostic Systems Co., Ltd, Tokyo, 
Japan) differs from that used in the FFLT (OC-Sensor Diana, Eiken Chemical Co., 
Ltd, Tokyo, Japan). Although these two FIT systems gave the same clinical 
outcomes in an asymptomatic screening programme, this result was achieved using 
the same positivity and not the same f-Hb threshold (31) exactly as in a comparison 
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of two FIT systems performed in the Netherlands, (32) and as recommended as the 
strategy for comparison of FIT systems. (33) Secondly, the SBoSP data are from 
November 2017 to April 2019 and the FFLT data were generated from July 2010 to 
December 2010.  Although data was obtained from the same two NHS Boards, the 
population demographics may have changed, particularly since the uptake in the 
SBoSP is higher than in the FFLT, especially among men, younger participants and, 
most importantly for f-Hb distributions, the more deprived. (20) Moreover, data from 
the pre-FIT gFOBT-based SBoSP demonstrated increasing positivity with time, 
indicating an increase in background occult gastrointestinal bleeding in the Scottish 
population (34).  Thus, overall, whatever the reason for the higher f-Hb in the SBoSP 
than in the FFLT, the results of a pilot evaluation based on a small proportion of the 
intended target population should clearly be interpreted with caution. While providing 
high-level predictive data, such an evaluation cannot obviate the need for careful 
monitoring of the performance of a newly introduced screening programme and even 
changes to the f-Hb threshold to accommodate colonoscopy capacity may become 
necessary as in The Netherlands (35) and elsewhere. The means to undertake this 
essential monitoring have been described previously: our results support use of the 
advocated strategies. (23) 
 
The data on the f-Hb distributions from the FIT-based SBoSP differ from those from 
the three other countries for which data in a similar format are available (6,7), 
confirming our previous findings that, while f-Hb is higher in men than in women in all 
age groups and rises with age in all countries, Scotland remains different to other 
countries.  This implies that, since clinical outcomes depend on positivity, which is 
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directly related to the f-Hb threshold applied, screening programme outcomes are 
unlikely to be directly transferrable between countries. 
 
 
The question arises whether this large database should be used to create sex, age, 
SIMD and NHS Board partitioned reference values for f-Hb, since screening is 
supposedly for asymptomatic individuals and our data could be considered to 
represent a reference sample group. The 97.5th percentiles given in Tables 1, 2 and 
4 would be the non-parametric upper reference limits of the 0.95 inter-fractile 
reference interval as recommended in the globally accepted Clinical Laboratory 
Standards Institute guideline CLSI C28-A3c. (35) The limitations of this approach 
have been documented in detail previously (5) and include that, although it is likely 
that our population does likely contain healthy individuals in the greatest number, 
some may be taking drugs or have colorectal conditions other than CRC, which may 
cause bleeding into the gut. In consequence, as previously, we consider that 
population-based reference intervals for f-Hb would be of very limited value. 
 
It would be possible to use these data to set different thresholds for invitation to 
further investigation by sex, age, SIMD and NHS Board.  However, this would be 
complex to initiate and execute.  Further, it would be very difficult to decide on what 
basis such partitioned thresholds should be set.  Programme positivity is the variable 
of greatest interest.  Positivity is higher in men than women, increases with age and 
is higher in the more deprived, exactly as f-Hb.  However, CRC is more common in 
men than women, in older participants and in the deprived and, in addition to 
significant advantages for organisation and delivery of a screening programme, use 
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of a single f-Hb threshold does generally direct further investigation to those most 
likely to have colorectal neoplasia. 
 
 
Since f-Hb is affected by sex, age, deprivation and geography, it might be 
considered that a multi-variate risk score incorporating these, and perhaps other 
variables, would be of value in ensuring that further investigation is offered to those 
that would most benefit. Clinical outcomes would be required to create a derivation 
cohort for development of an algorithm and studies involving validation cohorts 
would be required, and then prospective studies. This would seem to be complex to 
organise and execute in an already rolled-out successful screening programme. 
Further, it might be a difficult approach to explain to participants, the public, other 
health professionals, government and other stakeholders such as charities. In 
addition, f-Hb varies in different countries and seemingly with FIT system, participant 
characteristics and other variables, so mathematical risk scoring algorithms would be 
very unlikely to be transferable over geography or time.  
 
However, it might be that a simple approach using f-Hb and expressing the 
participant’s result as a centile of the relevant population group would have 
significant advantages.  We have determined the distribution of f-Hb by sex, age, 
SIMD and NHS Board in this study.  We plan now to examine the relationships 
between f-Hb centiles and the outcomes in the SBoSP to assess whether a simple 
centile-based threshold appropriate to the individual participant would lead to better 
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Legends to Figures 
 
Figure 1. 95th centiles of faecal haemoglobin concentration (µg Hb/g faeces) 
in all participants by sex and by sex and age quintile (years). 
 
Figure 2. 95th centiles of faecal haemoglobin concentration f-Hb (µg Hb/g 
faeces) in men by age quintile (years) and Scottish Index of Multiple 
Deprivation (SIMD) quintile. 
 
Figure 3. 95th centiles of faecal haemoglobin concentration (µg Hb/g faeces) 
in men by four age groups (years) in the Scottish Bowel Screening 
Programme (SBoSP), FIT as a first-line test (FFLT), Taiwan, Florence and 
Barcelona. 
 
 
 
 
